Gender differences in HIV drug resistance mutations and virological outcome

Journal of Women's Health

Volumn 20, Issue 1, 2011, Pages 117-122

  Mave, Vidya ^a   Gahunia, Mona ^b   Frontini, Maria ^b   Clark, Rebecca ^b   Mushatt, David ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS C; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIXED INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUBERCULOSIS; VIRUS ATTENUATION; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; NEW ORLEANS; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 79251470450     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1846     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Department of Health and Human Services (DHHS). Guidelines for use of antiretroviral agents in HIV infected adults and adolescents. Available at www.aidsinfo.nih? contentfiles/AdultAdolescentGI.pdf
3. Hammer SM, Saag MS, Schechter M, et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006;296:827-843.
4. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. Available at www.who.int/hiv? pub/guidelines/artadultguidelines.pdf
5. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
6. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-1401.
7. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279:1977-1983.
8. Coffin JM. HIV population dynamics in vivo: Implication for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-489.
9. Mayers DL. Drug resistant HIV-1: The virus strikes back. JAMA 1998;279:2000-2002.
10. Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf M, Peng G, Xiang Y, for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral nä?ve participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007;8:357-370.
11. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
12. Philips AN, Dunn D, Sabin C, et al., UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long-term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
13. Wyl VV, Yerly S, Boni J, et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofo-vir. Clin Infect Dis 2008;46:1299-1309.
14. Hirsch M, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodefi-ciency virus type 1: 2003 recommendations of an International AIDS-Society-USA panel. Clin Infect Dis 2003;37:113-128.
15. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for use of HIV-1 drug resistance test-ing as a part of treatment management: Recommendations for European setting. AIDS 2001;15:309-320.
16. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender dif-ference in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002;31:11-19.
17. Murri R, Lepri AC, Phillips, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A study. J Acquir Immune Defic Syndr 2003;34:184-190.
18. Turner BJ, Lane C, Cosler L, et al. Relationship of gender, depression and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003;18:248-257.
19. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: Does it help gender dis-parities in HAART use? J Womens Health 2006;15:173-181.
20. Toulomi G, Pantazis N, Antoniou A, et al. CASCADR col-laboration. Highly active antiretroviral therapy interruption: Predictors and virological and immunological consequences. J Acquir Imune Defic Syndr 2006;42:554-561.
21. Cressey TR, Lallemant M. Pharmacogenetics of anti-retroviral drugs for the treatment of HIV-infected patients: An update. Infect Genet Evol 2007;7:333-342.
22. Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2006;2:273-283.
23. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354.
24. Cooper D, Gatell J, Rockstroh J, et al., BENCHMRK-1 Study Group. 48-Week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with triple-class resistant HIV-1 [abstract 788]. In: Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic In-fections, Boston. Alexandria, VA: Foundation for Retro-virology and Human Health, 2008.
25. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a ran-domized, double-blind, placebo controlled trial. Lancet 2007;370:29-38.
26. Johnson M, Campbell T, Clotet B, et al. DUET-2: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs. placebo in 591 treatment-experienced HIV-1-infected patients [abstract 791]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2008.
27. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-465.
28. McKenna M, Hu X. Recent trends in the incidence and morbidity that are associated with perinatal human immu-nodeficiency virus infection in the United States. Am J Ob-stet Gynecol 2007;197(Suppl 3):S10-16.
29. Tai J, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active anti-retroviral therapy. J Infect Dis 2007;196:1044-1052.